|It is the intention of NeuroScios to provide the best possible service in every step of drug development to our clients. In the cumulated 35 years of work in drug development for CNS disorders the team of NeuroScios gathered enormous experience with spontaneous, induced and transgenic/KO-models of brain disorders, in particular in the field of neurodegenerative diseases. The team has been involved in development of hundreds of compounds, representing different classes of pharmacologically active substances developed for treatment of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, cerebrovascular disorders and other brain diseases. To continue providing these research services in a seamless way to our customers NeuroScios entered into an exclusive partnership with PsychoGenics Inc (www.psychogenics.com), a world leading preclinical contract research organization.|
PsychoGenics builds on more than 15 years of experience in behavioral research, and offers practically all standard tests for cognition, motor function, psychiatric disorders and pain. In addition they developed proprietary tests, utilizing advanced computer vision, robotics and state of the art bioinformatics for analysis of complex behavioral patterns. These ground breaking developments allow detailed analysis of drug action, and a powerful database can help analyze activities of any new compound in comparison with known active substances. PsychoGenics provides full-service, including in vitro and in vivo electrophysiology, brain biochemistry, immunohistochemistry and quantitative histopathology.
|PsychoGenics has in licensed and validated induced and transgenic animal models of neurodegenerative diseases including, AD, PD, ALS, Huntington's disease and many other orphan disorders. Their models have been used by leading pharmaceutical companies and are characterized by robust, reproducible pathology and functional deficits closely resembling human disease. Combined with years of experience of their scientific team this guarantees clients access to outstanding disease models and research quality. NeuroScios knows many service providers in the field, but we see it as our responsibility to offer the optimum quality for our clients.|